[Phase 2 study with cis-dichlorodiaminoplatinum (II) in advanced solid tumors].
cis-Dichlorodiammineplatinum(II) was administered in 23 patients with far advanced solid malignancies using a dose schedule of 50 mg/m2 every 3 weeks. All patients previously had progressive disease using conventional cytotoxic therapies. More than 50% of the patients had been pretreated with at least four different drugs, 9 patients had additionally been irradiated. IN 4 patients there was objective tumor regression (duration 1-4 months); in 7 patients tumor progression could be stopped for at least 1 month; 12 patients did not respond. By sufficient fluid administration combined with electrolyte substitution, furosemide and mannitol, no severe toxic side effects were encountered.
D001943:Breast Neoplasms / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy
D002945:Cisplatin
Phase-2-Studie mit cis-Dichlorodiaminoplatinum (II) bei weit fortgeschrittenen soliden Tumoren.